Somatic mutations in BRAF have been found in 1-4% of all NSCLC most of which are adenocarcinomas and may be a potential therapeutic target in some settings.
Dabrafenib + Trametinib
Robinson SD et al . BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer. 2014 Aug;85(2):326-30.
Paik PK et al.. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncology, 2011 May 20;29(15):2046-51.